Overview

A class action lawsuit has been filed against Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ : ERAS), and certain of the Company’s senior executive officers (collectively, “Defendants”), alleging violations of the federal securities laws. The Erasca lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Erasca common stock between January 14, 2025, and April 26, 2026, inclusive (the “Class Period”). Investors have until August 10, 2026, to seek appointment as lead plaintiff of the Erasca class action lawsuit.

Erasca is a clinical-stage precision oncology company focused on developing therapies for patients with certain types of cancers. One of the Company’s lead drug candidates is ERAS-0015, a molecular glue designed to treat patients with certain types of solid tumors.

Throughout the Class Period, Erasca promoted ERAS-0015 as a potential “best-in-class” therapy and repeatedly highlighted preclinical data that purportedly demonstrated superior potency and antitumor activity compared to Revolution Medicines’ competing product candidate, RMC-6236. The complaint alleges that these statements were materially false and misleading because ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines and placed Erasca at risk of violating patent and trade secret protections. 

The truth began to emerge on April 27, 2026, when Erasca disclosed that it had received a letter from counsel for Revolution Medicines alleging that ERAS-0015 infringed a Revolution Medicines patent and was connected to alleged trade-secret misappropriation. Revolution Medicines also asserted that Erasca had improperly compared preclinical data for ERAS-0015 and RMC-6236 in public disclosures and demanded that the Company cease making allegedly deceptive comparative statements. On this news, Erasca’s stock price fell nearly 11%, falling from $21.49 per share on April 24, 2026, to close at $19.15 per share on April 27, 2026.

Later that same day, Erasca released preliminary Phase 1 clinical data for ERAS-0015 and disclosed that a patient receiving the drug candidate had died after experiencing treatment-related pneumonitis. The Company also acknowledged that comparisons between ERAS-0015 and competing therapies, including RMC-6236, were based on cross-study analyses rather than head-to-head clinical trials and were therefore inherently limited. Following these disclosures, Erasca’s stock price fell more than 48%, declining from $19.15 per share on April 27, 2026, to close at $9.90 per share on April 28, 2026.

*          *          *

If you purchased or otherwise acquired Erasca common stock between January 14, 2025, and April 26, 2026, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt attorneys Brian O’Mara and Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Erasca class action lawsuit is August 10, 2026.